SEC EDGARAUG 201 min read$CAH

Mason Stephen M sold $8.3M of CAH

Mason Stephen M (CEO, GMPD Segment) sold 35,000 shares of CARDINAL HEALTH INC (CAH) at an average of $236.40 ($234.59–$237.26, $8.27M total) across 4 trades on 2026-08-18.

Original reporting

SEC EDGAR · Mason Stephen M

Published Aug 20, 2026, 11:30 AM UTC

Analysis

alphai AI DeskAI-generated

Added to alphai Aug 20, 2026, 11:38 AM UTC. Informational, not investment advice.

How this was made

alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About alphai AI Desk Scoring methodology Report an issue

alphai market briefInsider activity

Primary signal

$CAH

Bearish

medium confidence

Mentioned

$CAH

Relevance

6/10

alphai data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$CAHBearishLow

Why it matters

The $8.3M sale is the first public disclosure of this insider activity, providing new data for valuation models.

Market read

The insider sale adds fresh negative sentiment for CAH and may trigger short‑term price adjustments.

What to watch

CEO may have tax or liquidity reasons; the remaining stake remains large.

Relevance 6/10Novelty 7/10Timing: filing date 2026-08-20

Background

Form 4 filings disclose insider transactions; a CEO sale is closely watched by traders.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$CAHBearishMedium confidence

Context

CEO Mason Stephen M sold 35,000 shares for $8.27M, reducing his stake to 18,061 shares.

Expected impact

downward pressure in the near term

Evidence & confidence

A $8.3M open‑market sale by the chief executive is material and suggests potential concerns, but the remaining stake is still sizable.

Market effects

Sector

Minimal impact on the healthcare distribution sector beyond CAH.

Regional

U.S. market only; no broader regional effect.

Global

Limited to investors tracking CAH.

Counterpoint

What could challenge this read

The sale could be a routine diversification rather than a bearish signal.

Key entities

Company
Cardinal Health Inc.
U.S. healthcare services and products distributor.
Executive
Mason Stephen M
CEO of Cardinal Health's GMPD segment.

Read at source ← All news

SEP 7

$CAHMedAI 8/10

4 companies on verge of settling US opioid lawsuits

AmerisourceBergen, Cardinal Health, McKesson, and Johnson & Johnson are nearing a $26B settlement for opioid lawsuits. New York reached a separate $1B deal with the distributors. Johnson & Johnson will contribute up to $5B nationally. Trials continue elsewhere.

pressdemocrat.com3 min

SEP 3

$CAHHighAI 8/10

Jim Cramer Notes Cardinal Health (CAH) is “Too Attractive to Ignore”

Jim Cramer highlighted Cardinal Health (CAH) as a favorite, citing its specialty pharmaceuticals and healthcare services growth. Q4 revenue rose 6% to $63.7B but missed estimates, while adjusted EPS was $2.91. Fiscal 2027 guidance includes non-GAAP EPS of $12.40-$12.60 and adjusted free cash flow of $3.5B-$4B. Risks include execution, drug pricing, and customer concentration.

insidermonkey.com3 min

AUG 20

$CAHMed

Hollar Jason M. sold $29.4M of CAH

Hollar Jason M. (Chief Executive Officer) sold 124,529 shares of CARDINAL HEALTH INC (CAH) at an average of $235.89 ($233.22–$237.88, $29.38M total) across 10 trades over 2026-08-18 to 2026-08-19.

SEC EDGAR1 min

AUG 19

$CAHHighAI 8/10

Cardinal Health’s (CAH) Big Earnings Beat Hides a More Complicated Story

Cardinal Health (CAH) reported Q4 2026 earnings with non-GAAP EPS up 40% YoY to $2.91, including a $0.31 one-time tariff refund. Revenue reached $63.7B, up 6% YoY. Full-year adjusted free cash flow hit $5B. Guidance suggests slower growth ahead. The company expanded its buyback program by $5B to $6.4B.

yahoo.com2 min

AUG 18

$CAHHighAI 9/10

Cardinal Health (CAH) Q4 2026 Earnings Call Transcript

Cardinal Health (CAH) reported Q4 2026 revenue of $63.7B, up 6%, driven by Pharmaceutical and Specialty Solutions. Non-GAAP EPS was $2.91, up 40%. Fiscal 2027 guidance includes 3-5% pharma revenue growth and 8-11% profit growth. The company plans $1B in share repurchases and increased its authorization to $6.4B. Management cited risks from geopolitical instability and IRA price changes.

fool.com6 min